[Seasonal flu vaccination for older people: Evaluation of the adjuvanted vaccine. Positioning report].
| Autor: | López Mongil R; Geriatría, Centro Asistencial Doctor Villacián, Valladolid., López Trigo JA; Presidencia de la Sociedad Española de Geriatría y Gerontología (SEGG), Geriatría, Ayuntamiento de Málaga, Málaga. Electronic address: joselopeztrigo@gmail.com., Mariano Lázaro A; Medicina Preventiva y Salud Pública, Unidad de Epidemiología, Servicio de Medicina Preventiva, Hospital Clínico San Carlos, Madrid., Mato Chaín G; Medicina Preventiva y Salud Pública, Unidad de Vacunación del Adulto, Servicio de Medicina Preventiva, Hospital Clínico San Carlos, Madrid., Ramos Cordero P; Geriatría, Agencia Madrileña de Atención Social, Consejería de Políticas Sociales y Familia, Comunidad de Madrid, Madrid., Salleras Sanmartí L; Cátedra de Medicina Preventiva, Universidad de Barcelona, asesor, consultor, Barcelona. |
|---|---|
| Jazyk: | Spanish; Castilian |
| Zdroj: | Revista espanola de geriatria y gerontologia [Rev Esp Geriatr Gerontol] 2017 Nov; Vol. 52 Suppl 2, pp. 1-14. |
| DOI: | 10.1016/S0211-139X(18)30086-6 |
| Abstrakt: | Flu is a major public health problem, particularly for older people, and creates an important clinical and economic burden. A high mortality rate was reported in Spain during the period 2015 to 2016; 3,101 serious cases were hospitalised with a confirmed diagnosis of flu, of which 11% died (352 cases). Furthermore, financial and health costs are greatly increased by the complications of flu; people aged over 65 years represent approximately 64% of the total costs. Seasonal flu vaccination is the fundamental strategy, as demonstrated by cost-benefit and cost-effectiveness studies. A priority objective is to improve the vaccine's immune response and the search for and inclusion of adjuvants and immunostimulants in vaccines is a major line of research. This positioning report evaluates vaccination for older people and the importance of the adjuvanted vaccine in the elderly in strengthening immunogenicity, by means of a critical review of the literature based on the best evidence available on its immunogenicity and effectiveness, and an economic assessment. (Copyright © 2017 Sociedad Española de Geriatría y Gerontología. Publicado por Elsevier España, S.L.U. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|